Skip to main content
. 2020 Jun 9;38(28):4476–4483. doi: 10.1016/j.vaccine.2019.09.074

Fig. 2.

Fig. 2

Seroconversion rates as measured by anti-Vi IgG ELISA Response. [Note] Seroconversion rate is proportion of participants who had 4-fold rise in titers compared to baseline (Day 0, Week 0) to post dose. Among all participants the difference in seroconversions post single dose compared to the placebo group was statistically significant (P < 0.0001).